Last reviewed · How we verify
NCT05679856: VC-Larynx
Vocal Cord vs Whole Laryngeal Radiotherapy for T1aN0 Glottic Cancer
NA trial testing Hypofractionated single vocal cord irradiation in Larynx Cancer Stage I in 50 participants. Status unknown.
1 December 2023
Quick facts
| Lead sponsor | National Cancer Institute, Egypt |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 1 January 2020 |
| Primary completion | 1 December 2023 |
| Estimated completion | 1 December 2023 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Hypofractionated single vocal cord irradiation
- Whole laryngeal radiotherapy
Conditions studied
- Larynx Cancer Stage I — all drugs for Larynx Cancer Stage I →
- Glottic Carcinoma — all drugs for Glottic Carcinoma →
Sponsor
National Cancer Institute, Egypt
Who can join
18 and older, any sex, with Larynx Cancer Stage I or Glottic Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary objective of this prospective randomized clinical trial is to assess non inferiority in terms of local control achieved with single vocal cord hypofractionated radiotherapy compared to standard of care whole laryngeal radiotherapy in patients with T1aN0 glottic cancer . Secondary objectives include overall survival rate and to compare the Voice Handicap Index score between the 2 arms as well as acute and late toxicities. Patients are randomized in 1:1 ratio.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Single vocal cord irradiation (SVCI) vs whole laryngeal radiotherapy in the treatment of T1aN0 glottic cancer A prospective randomized trial.
Elsharief MM, Hassouna AH, Shouman T, Mosallam A, et al · · 2026 · PMID 41520731 · DOI 10.1016/j.radonc.2026.111376
Verify or expand the search:
- PubMed search for NCT05679856
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other National Cancer Institute, Egypt trials
Trials by the same sponsor.
- NCT07424638 — Interscalene Block Versus Anterior Suprascapular Block for Post-Thoracotomy Shoulder Pain · NA · recruiting
- NCT07367568 — Costotransverse Foramen Block With Erector Spinae Plane Block in Modified Radical Mastectomy · NA · recruiting
- NCT07367581 — Costotransverse Foramen Block Versus Thoracic Paravertebral Block in Thoracotomy for Lung Cancer · NA · recruiting
- NCT07337330 — Ultrasound Guided External Oblique Intercostal Plane Block Versus Erector Spinae Block for Post Hepatectomy Pain · NA · not yet recruiting
- NCT07390448 — Rhomboid Intercostal Sub-serratus Plane Blocks and Erector Spinae Plane Block in Mastectomy Surgeries · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05679856 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Cancer Institute, Egypt
- Last refreshed: 11 January 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05679856.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing